RT Book, Section
A1 Granwehr, Bruno P.
A1 Chemaly, Roy F.
A1 Kontoyiannis, Dimitrios P.
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
SR Print(0)
ID 1126746113
T1 Fungal and Viral Infections in Cancer Patients
T2 The MD Anderson Manual of Medical Oncology, 3e
YR 2016
FD 2016
PB McGraw-Hill Medical
PP New York, NY
SN 9780071847940
LK hemonc.mhmedical.com/content.aspx?aid=1126746113
RD 2021/02/25
AB Fungal  and  viral  infections  remain  a  significant  cause  of  morbidity  and  mortality  in  patients  with  cancer.  Modern  management  of  infections  in  cancer  requires  knowledge  of  the  epidemiology,  pathogenesis,  treatment,  and  prevention  of  such  infections.  Fungal  infections  range  from  nosocomial  infections  with  Candida  spp  to  endemic  fungi  acquired  outside  the  hospital,  such  as  Histoplasma  capsulatum.  Opportunistic  fungi,  especially  molds,  have  emerged  as  a  leading  cause  of  death  in  patients  with  leukemia  or  hematopoietic  stem  cell  transplant  (HSCT)  (1).  Viral  infections  such  as  varicella  zoster  virus  (VZV),  herpes  simplex  virus  (HSV),  or  cytomegalovirus  (CMV),  have  been  associated  with  increased  morbidity  and  mortality  in  patients  with  cancer,  including  patients  with  multiple  myeloma  or  chronic  lymphocytic  leukemia  (CLL),  and  in  HSCT  recipients  (2,3,4,5).  Respiratory  viruses,  such  as  respiratory  syncytial  (RSV),  adenovirus,  and  influenza,  are  increasingly  recognized  as  significant  pathogens  in  patients  with  cancer,  particularly  as  molecular  diagnostic  methods  improve.  In  addition,  viruses  such  as  novel  influenza  H1N1,  West  Nile  virus,  bocaviruses,  and  noroviruses  have  emerged  as  newly  recognized  pathogens  in  patients  with  cancer.